Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is just the beginning ......
grtz
Nanalysis Scientific Corp. Announces $160 Million Multi Year Contract Win
Calgary, Alberta, May 26, 2022 Nanalysis Scientific Corp. (TSXV:NSCI, OTCQX:NSCIF, FRA:1N1) (“Nanalysis” or the “Company”) announces that the Company’s wholly-owned subsidiary K’(Prime) Technologies (KPrime) has won a six year $160 million service and maintenance contract with Canadian Air Transportation Security Authority (“CATSA”), which includes a gradual phase in period of approximately one year. Furthermore, it is common for these types of contracts to be renewed for an additional five years, making it a potential 11 year recuring revenue opportunity, with inflation-based contractual price increases. The effective date of the executed contract is May 25, 2022 and it expires on May 31, 2028.
“We are pleased to have won this contract to support imaging and other security screening equipment at all airports across Canada,” said Sean Krakiwsky, Founder and Chief Executive Officer of Nanalysis. “The security market is a very important vertical for all our products, including benchtop NMR, and it is our vision to have direct sales and service capabilities in every major market in the world. This contract win is an instrumental step in simultaneously opening up the security vertical as well as adding a material recurring revenue stream to our business. In addition to world-class R&D and manufacturing, we are now a world-class equipment service provider. We expect to expand this business in the security vertical, globally, as part of our growth plans going forward.”
KPrime has begun the phase in process for this project to airports across Canada, and the company anticipates the service coverage to be completed before the end of Q1, 2023.
Martin Corrigan, Vice President and CTO of CATSA states: “We look forward to working with KPrime as they assume the maintenance service responsibilities for our of large fleet of screening equipment across the country.”
Kham Lin, Founder and President of KPrime and Managing Director of Nanalysis’ Security Business, states: “We have been positioning KPrime to win this contract for several years but needed to be part of a larger organization to conduct business of this size. This contract win is one example of how Nanalysis + KPrime will enable larger business opportunities and value creation for shareholders. We currently provide service in airports and other security markets, and so we are well positioned to expand this business. This business also opens sales channels for Nanalysis’ proprietary products going forward. Because of our experience with these types of service contracts, we are very confident in our ability to successfully implement and profitably manage this world-class project.”
Airports, border crossings, prisons, and other security markets are expected to be important growth drivers for Nanalysis over the next five years and beyond. Nanalysis’ vision is to build a fully vertically integrated global scientific instrumentation company, serving customers in the security, pharma, biotech, food, energy, advanced materials, petrochemical, healthcare, and education markets with imaging and detection products and service. The company will continue to expand direct sales, service, and channel management capabilities world-wide, and will also strengthen technology partnerships, as well as develop important supply chain risk-mitigation and technology differentiation capabilities as geo-political landscape evolves, ensuring the ability to continue to drive growth and create shareholder value.
A 40% discount from the Nov high makes Nanalysis even more interesting as a long term investment.
Ombow - (OT) Btw, nice call with VERU.
---
Overview info - >>> Nanalysis (NSCI) - Presentation, Deep Dive, Interview, Q&A - CEO Sean Krakiwsky & CFO Luke Caplette -
>>> Nanalysis Provides Corporate Update
MarketWatch
Feb. 17, 2022
https://www.marketwatch.com/press-release/nanalysis-provides-corporate-update-2022-02-17?siteid=bigcharts&dist=bigcharts&tesla=y
CALGARY, AB, Feb. 17, 2022 /PRNewswire via COMTEX/ -- Holding Call at 5pm ET Today
CALGARY, AB, Feb. 17, 2022 /PRNewswire/ Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR and MRI machines for healthcare and industrial applications, provides a corporate update and will be holding at call at 5:00pm ET today.
"Our growth trajectory continued though the end of 2021 and continues today," said Sean Krakiwksy, Chief Executive Office of Nanalysis. "After a solid fourth quarter we closed a banner year in 2021 for Nanalysis. Over a month ago we closed our acquisition of K'Prime and subsequently announced the acquisition of Quad Systems. We couldn't have been more pleased with the interest in our recent equity offering, resulting in an upsizing to satisfy demand. As I look into 2022, we will not be entering into any other acquisitions, we will focus on the integration of K'Prime and Quad Systems and focus on growing our sales with our current and future products. We truly believe we have set the stage to continue our growth trajectory into 2022, 2023 and beyond."
Financial Highlights (unaudited):
Annual gross revenues for the twelve months ended December 31, 2021 of approximately $16 million, representing an increase of up to 103% year over year.
Gross margins anticipated in the range of 63% to 65% for the twelve months ended December 31, 2021.
Recent strategic and operational highlights include:
Closed Marketed public offering and private placement for combined gross proceeds of $15,224,700: These funds will be used to complete the acquisition of QUAD systems, provide working capital and accelerate organic growth.
Announced Acquisition of Quad Systems: As part of the agreement, Nanalysis has provided Quad Systems with a CHF 1,000,000 loan (Loan) which is convertible into shares in the capital of Quad Systems, Nanalysis will the subscribe for 260,000 Quad Systems shares for cash consideration of CHF 6,500,000 (Equity Investment). On completion of the Equity Investment a second representative of Nanalysis will be appointed to Quad Systems' Board of Directors. At this stage, Nanalysis will own 43% of Quad Systems. Until July 1, 2023 (Option Period), Nanalysis has an option (Option) to acquire 100% of the issued and outstanding shares of Quad Systems at a pre-set valuation formula in a combination of cash and majority Nanalysis shares. During the Option Period, Nanalysis has a right of first refusal on all debt and equity offerings of Quad Systems.
Announced closing of the acquisition of K'(Prime) Technologies ("Kprime"): Kprime a North American sales and service company, with a particular focus on scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems for security applications. Over the past four fiscal years KPrime's unaudited revenue has been between C$8 million and C$10 million with positive EBIDTA(1) of roughly $1.0 to $1.5 million per year.
The Company delivered 13 100 MHz units in the Fourth Quarter and as at February 17, 2022 has 31 on back order. The expansion of the manufacturing facility has been completed and the newly trained manufacturing personnel are ramping up production.
Outlook
Sean Krakiwsky states, "Our current business for our flagship products, the 100MHz and 60MHz, remains very strong and we see this continuing. We are now able to continue to expand with a full sales and service organization in multiple additional channels with the addition of K'Prime. Conversely, K'Prime can now pursue RFP's and contracts that they were previously unable to as a stand-alone company. Quad Systems allows us to enter the high-end part of the market, expand our product line offerings and to leverage the capabilities of both Company's technology suites. We are confident these acquisitions will both help fuel our growth for the years to come."
Conference Call
Chief Executive Officer Sean Krakiwsky and Chief Financial Officer Luke Caplette will host a conference call to discuss these results at 5:00 P.M. Eastern time today. All interested parties are invited to join this call.
Investors interested in participating on the live call can dial 1-877-451-6152 or 1-201-389-0879 from abroad. Investors can also access the call online through a listen-only webcast
https://themediaframe.com/mediaframe/webcast.html?webcastid=jAnyFUII, or on the investor relations section of the Company's website HERE.
The webcast will be archived on the Company's investor relations webpage for at least 90 days and a telephonic playback of the conference call will be available by calling 1-844-512-2921 or 1-412-317-6671 from abroad. The conference ID is 13727085. Telephonic playback will be available for 14 days after the conference call.
The preliminary estimated financial results and other data for the twelve months ended December 31, 2021 set forth above are subject to the completion of the Company's financial closing procedures. This data has been prepared by, and is the responsibility of, the Company's management. Ernst & Young, Nanalysis' independent firm of Chartered Professional Accountants, does not express an opinion or any other form of assurance with respect thereto. The Company currently expects that its final results of operations and other data for the year ended December 31, 2021 will be consistent with the estimates set forth above, but such estimates are preliminary and Nanalysis actual results of operations and other data could differ materially from these estimates due to the completion of its annual audit procedures, final adjustments, and other developments that may arise between now and the time such audited consolidated financials statements for the twelve months ended December 31, 2021 are released.
(1)Use of Non-GAAP Measures
Nanalysis reports on certain financial performance measures that are described and presented in order to provide shareholders and potential investors with additional measures to evaluate Nanalysis ability to fund its operations and information regarding its liquidity. In addition, these measures are used by management in its evaluation of performance. These financial performance measures ("Non-GAAP Terms") are not recognized financial terms under Canadian generally accepted accounting principles ("Canadian GAAP"). For publicly accountable enterprises, such as Nanalysis, Canadian GAAP is governed by principles based on IFRS and interpretations of IFRIC. Management believes these Non-GAAP Terms are useful supplemental measures. These Non-GAAP Terms do not have standardized meanings and may not be comparable to similar measures presented by other entities. Specifically, Working capital and EBITDA are not recognized terms under IFRS and do not have standardized meanings prescribed by IFRS.
About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)
Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', Over the Counter (OTC) in the United States under the ticker symbol 'NSCIF', and on the Frankfurt Exchange (FRA) under the symbol '1N1'.
Nanalysis is an international business focused on capitalizing its proprietary technologies in nuclear magnetic resonance (NMR) that go into NMR spectrometers and magnetic resonance imaging (MRI). Nanalysis operates out of two subsidiaries, Nanalysis Corp. and RS2D S.A.S. (RS2D).
Nanalysis Corp. is an industry leader in developing and manufacturing compact NMR spectrometers for laboratory and industrial markets. Its advanced 60 and 100 MHz spectrometers require no liquid helium or other cryogens. These devices are used by chemical professionals spanning a wide variety of industries, including oil and gas, chemical, mining, pharmaceutical, and biotechnology.
Through its European subsidiary RS2D, the Company's electronic boards and software are used in conventional NMR and MRI equipment and are being incorporated into next-gen MRI systems as well as miniaturized MRI devices.
<<<
---
thanks Walter ,
I also saw they added 10 career opportunities ,
grtz
no news.
whati is important for me is that nanalysis hopes to double their revenue year over year..
Hello Walter , is there any news ? I can see there are brutal movements
these days .
grtz
Hello Walter ,
The numbers as expected , 100% growth , but what i like the most
is " agressive expansion plans to continue to meet demand " ,
grtz ,
a Belgian investor
they report indeed in CAD
Hi Walter,
guess all values we discuss here are CAD$ not USD$, correct?
Thanks for sharing that, Walter. Very good presentation.
Thanks Walter ,
I think we should be happy to be part of this in the early stages .
If you look at the market cap , there is a huge potential .
For me , the only thing it misses is a certain vibe , what we have seen with
lwlg , i mean , at this moment it is not known as it should be ....
What about the listing ?
Perhaps one day , this train will leave the station , and get the attention
of a broad public . I am in for the long haul !!
thanks again Walter ,
grtz
the presentation was this week.
Hi Walter, thank you for posting Sean's presentation video. Very interesting.
Thanks for sharing, Walter. On my phone so not seeing any timeline on when this presentation took place. By chance was this recent? Heavy (for me) in LWLG, however hoping to find some funds to get a position as I do more DD of my own for NSCIF. As always, appreciate you generous sharing!
Mike
Ceo Sean is not only a good golf player and a top icehockey player ( I played with him in Brasschaat Golf club in Belgium- ) where he also g ave afterwards a presentation to 65 investors but also a very enthusiastic presenter for his company where he was the founder..
watch this new video https://noble.mediasite.com/Mediasite/Play/116e75104b074f3491ff20780ccca2af1d
In this video he forecasted revenues for nanalysis
in 2021 16 million
in 2022 35 million
in 2023 75 million
I think this is going to become a 2nd LWLG for me..
Nanalysis Scientific Corp. Announces $4,985,000 Funding Contribution from the Canadian Government
Calgary, Alberta, March 17, 2022 Nanalysis Scientific Corp. (TSXV:NSCI, OTCQX:NSCIF, FRA:1N1) (“Nanalysis” or the “Company”) announces that the Company has received repayable funding of $4,985,000 to expand manufacturing operations and global markets for nuclear magnetic resonance products from the government of Canada.
“We are very thankful for the support from the Canadian government,” said Sean Krakiwsky, founder and Chief Executive Officer of Nanalysis. “Nanalysis is thrilled to be one of the recipients from Prairies Economic Development Canada. This funding allows us to accelerate product innovation, expand our manufacturing capabilities, build up inventory levels to mitigate any supply chain issues and de-risk potential down time through redundant equipment. These funds will help enable us to continue to drive significant growth as we expand our global footprint.”
The funding is provided through Prairies Economic Development Canada’s (“PrairiesCan”) Business Scale-up and Productivity program, which provides fast growing tech firms with support to scale-up and enter new markets. Nanalysis will draw down on the funds over the next three years with interest-free repayments commencing on September 1, 2025.
super excited with the recent update.
quote.
In 5 years time Nanalysis will be 10 times what we are today. says the CEO.
This is positive news, yet the share price drops this morning. Odd.
CALGARY, AB, Feb. 11, 2022 /PRNewswire/ - Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") announces that it has closed the previously announced best efforts marketed public offering (the "Public Offering") of common shares (the "Common Shares") of the Company, including the full exercise of the over-allotment option and the non-brokered private placement of Common Shares (the "Private Placement") for combined gross proceeds of $15,224,700.70.
The broader market is heading south. Nanalysis is overvalued.
According to Yahoo Finance, statistics for NSCI.V show -
Forward P/E 44.84
Shares Outstanding 80.03M
Revenue $13.61 Million
Diluted EPS -0.0400
% Held by Institutions 0.13%
I believe the prospects for this company are very good in the long term, but the stock is not worth what it's presently selling for, IMO.
Thanks Walter
Nanlysis is one of them.
ORIGINAL: 36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022
2022-01-28 10:07 ET - News Release
RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th - 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.
The virtual conference begins on Tuesday, February 8th, 2022, with company presentations beginning at 8:30 am Eastern Time. Presentations will be webcast on Tuesday and Wednesday (February 8th and 9th) with 1x1 Meetings being held on Thursday and Friday (February 10th and 11th).
Join us for a full two days of presentations that were nominated by qualified investors as a "Best Idea." A preliminary agenda is located here: https://microcaprodeo.com/agenda
If you would like to attend and participate in the 2nd Annual Winter Wonderland Best Ideas Virtual Conference, please register here to listen to every webcast directly on the website and book 1x1 meetings with presenting companies: https://microcaprodeo.com/signup
Full event website: https://microcaprodeo.com/
On Tuesday February 8th and Wednesday February 9th, the following issuers will be presenting their companies virtually.
Organization
Ticker
Achieve Life Sciences
ACHV
AgriFORCE Growing Systems Ltd.
AGRI
Alimera Sciences
ALIM
Aspira Women's Health
AWH
Assertio Holdings, Inc.
ASRT
Biolase
BIOL
Charah Solutions
CHRA
Data Storage Corporation
DTST
Duos Technologies, Inc.
DUOT
Fortress Biotech
FBIO
Genasys Inc.
GNSS
Greenbox POS
GBOX
iCAD
ICAD
Issuer Direct Corporation
ISDR
LifeMD, Inc,
LFMD
Medexus Pharmaceuticals, Inc.
TSXV: MDP, OTCQX: MEDXF
Milestone Scientific
MLSS
Nanalysis Scientific Corp.
NSCI
NeuroOne Medical Technologies Corp.
NMTC
Nova Leap Health Corp.
NLH.V
Opera
OPRA
ProPhase Labs, Inc.
PRPH
PyroGenesis Canada Inc
TSX:PYR, NASDAQ:PYR
Red Cat Propware Inc
Senstar
SNT
Stran & Company, Inc.
STRN
Tego Cyber Inc.
TGCB
TETRA Technologies
TTI
Trust Stamp
IDAI
Vicinity Motor Corp.
NASDAQ:VEV
Please contact Angie Wright via email or at 919-228-6240 if you are interested in attending or simply register here and then select companies you are interested in meeting with in a 1x1 setting.
We look forward to seeing you at the conference.
About the MicroCap Rodeo Best Ideas Conferences
The MicroCap Rodeo is back with its fourth "Best Ideas" conference. This conference is a virtual conference that brings you the top 36 best ideas. Qualified institutional investors recommended each of the 36 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas, know that we're focused on alpha.
SOURCE: MicroCap Rodeo
The offering was oversubscribed . ( great success)
https://finance.yahoo.com/news/nanalysis-scientific-corp-announces-upsize-142800174.html
Nanalysis Named to 2022 OTCQX Best 50
Calgary, Alberta, January 24, 2022.Nanalysis Scientific Corp. (TSXV:NSCI, OTCQX:NSCIF, FRA:1N1) (“Nanalysis” or the “Company”) is pleased to announce it has been named to the 2022 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year.
The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX market. The ranking is calculated based on an equal weighting of one-year total return and average daily dollar volume growth in the previous calendar year. Companies in the 2022 OTCQX Best 50 were ranked based on their performance in 2021.
“We are delighted to receive this honor,” said Sean Krakiwsky, Chief Executive Officer of Nanalysis. “Our ranking is a result of our performance which comes from all of the hard work from all our employees and stakeholders.”
For the complete 2022 OTCQX Best 50 ranking, visit:
https://www.otcmarkets.com/files/2022_OTCQX_Best_50.pdf.
The OTCQX Best Market offers transparent and efficient trading of established, investor-focused U.S. and global companies. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws
The full release can be viewed here: https://www.newswire.ca/news-releases/nanalysis-named-to-2022-otcqx-best-50-840507739.html
I like the company and the management a lot, great prospectives. But what the heck. I recently supported the pps when it was on a serious downturn just to find out a couple of days later that they are issuing an offering at 1.1cad. Not the best timing!!!
I don't think timing is important here . They know what they are doing .
Some time ago they bought 5% of their own stock because they said that
the company was undervalued . So now they are acquiring another company
that suits in their trajectory of growth .
They are quite unique with their nuclear products of that size .
As Walter said , they could become a unicorn ...
They are building their business and will probably be profitable in the
near future . I like the company and the management and i am happy
to be in it now , this is only the beginning .
grtz
Any thoughts on the timing of this public offering seen the current pps and market sentiment?
Totally agree Walter , the company isn't valued as it should be
in my opinion ,
grts
another step with the goal of becoming a unicorn.
Good to see them continue to execute their plan. How many acquisitions did Sean say they were targeting for 2022? 2-3?
Thanks! Good man! But I think he is from Switzerland. eom
Nanalysis appoints Dr. René Lenggenhager to board of directors.
https://www.prnewswire.com/news-releases/nanalysis-appoints-dr-rene-lenggenhager-to-board-of-directors-301445268.html
Thanks for posting this . I like the company and the management .
Lots of potential !
grts
What about the results guys ? It is a very young company but i like
what i see ....
Seems like a good combination of skillsets and services to me.
K'(Prime) Technologies bringing sales network and skills along with a service organisation, which will is highly valuable to ramp up the sales of NSCI's products.
Now they got to make sure the production facility can handle the additional sales. Looking forward to it.
Thanks for posting the link
Fellow investors,
Research Capital ($3B CAD Assets Under Management) has initiated coverage on NSCI with a price target of $1.90. I invite investors to read the full report HERE.
We continue to gain more momentum in terms of raising awareness of our exciting story and hope to have more good news to you in the weeks to come.
As always, please contact me with any questions, feedback, or inquiries via phone or email using the contact details below and thank you as always for your continued support. To read the latest new on Nanalysis, please navigate to our Company News page by clicking HERE.
Best regards,
Matt Sellers
Investor Relations
Nanalysis Scientific Corp.
TSXV:NSCI, OTCQX:NSCIF, FRA:1N1
Mobile: +1.587.436.1291 (Whatsapp)
Office: +1.403.769.9499
nanalysis.com
Bay 1, 4600 – 5 St. NE, Calgary, Alberta, Canada T2E 7C3
Connect with us on Twitter and LinkedIn
That makes more sense. Thanks.
Followers
|
52
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
325
|
Created
|
12/01/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |